Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQ Grass 27600 SU in grass pollen-induced seasonal allergic rhinitis/rhinoconjunctivitis
2020-000408-13Phase 2Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- Apr 2020
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in seasonal allergic rhinitis (SAR) and allergic rhinoconjunctivitis (ARC) comparing PQ Grass 27600 SU with Placebo (2 arms). Primary endpoint: CSMS averaged over the peak grass pollen season. Started Apr 2020; status: completed.
02
Drugs
Grass MATA MPL
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2020-000408-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000408-13.